Clinical Trial Update: A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy and safety of IBI356 in participants with moderate-to-severe atopic dermatitis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• IBI356

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Atopic Dermatitis | Phase 2 | Status: RECRUITING